Revisiting Multi-Omics Data to Unravel Galectins as Prognostic Factors in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with a poor prognosis. Galectins (Gal) have been the subject of intensive research, but the comparative prognostic value of each Gal type is not yet understood. Therefore, a literature search for evaluating galectins as prognostic b...

Full description

Saved in:
Bibliographic Details
Published inBiomedicines Vol. 12; no. 3; p. 529
Main Authors Barros, Oriana, D’Agostino, Vito Giuseppe, Santos, Lucio, Ferreira, Rita, Vitorino, Rui
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 27.02.2024
MDPI
Subjects
B cells
Biomarkers
Cancer therapies
Cells
Chemotherapy
Comparative analysis
Datasets
Development and progression
galectins
Gene expression
Genomics
Head & neck cancer
Head and neck carcinoma
head and neck squamous cell carcinoma
Human papillomavirus
Internet software
Medical prognosis
Metastasis
multi-omics
Papillomavirus infections
Prognosis
RNA
RNA sequencing
Squamous cell carcinoma
Survival analysis
Tumor microenvironment
Tumor proteins
Tumors
Portugal
multi-omics
galectins
prognosis
head and neck squamous cell carcinoma
Online AccessGet full text
ISSN2227-9059
2227-9059
DOI10.3390/biomedicines12030529

Cover

Abstract Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with a poor prognosis. Galectins (Gal) have been the subject of intensive research, but the comparative prognostic value of each Gal type is not yet understood. Therefore, a literature search for evaluating galectins as prognostic biomarkers in HNSCC was conducted. The relationship between Gal expression in HNSCC with HPV and TP53 mutational status was assessed using the UALCAN database. The impact of these biomarkers on prognosis was analyzed using ToPP and CPPA web tools. The expression of galectins in the tumor microenvironment and the impact on prognosis depending on the cancer immune subtype were analyzed using single-cell RNA sequencing. Gal-1 and Gal-3BP were shown to be promising biomarkers with a triple function for the prediction of HPV and TP53 mutational status, stratification of the HNSCC prognosis, and prediction of the response to treatment. In addition, these two galectins have been shown to be most influenced by the tumor microenvironment of HNSCC. Gal-1 and Gal-3BP are the most promising galectins in HNSCC. Furthermore, this study highlights the need for further studies to evaluate galectins in HNSCC and clarify the role of individual Gals in the patient’s stratification.
AbstractList Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with a poor prognosis. Galectins (Gal) have been the subject of intensive research, but the comparative prognostic value of each Gal type is not yet understood. Therefore, a literature search for evaluating galectins as prognostic biomarkers in HNSCC was conducted. The relationship between Gal expression in HNSCC with HPV and TP53 mutational status was assessed using the UALCAN database. The impact of these biomarkers on prognosis was analyzed using ToPP and CPPA web tools. The expression of galectins in the tumor microenvironment and the impact on prognosis depending on the cancer immune subtype were analyzed using single-cell RNA sequencing. Gal-1 and Gal-3BP were shown to be promising biomarkers with a triple function for the prediction of HPV and TP53 mutational status, stratification of the HNSCC prognosis, and prediction of the response to treatment. In addition, these two galectins have been shown to be most influenced by the tumor microenvironment of HNSCC. Gal-1 and Gal-3BP are the most promising galectins in HNSCC. Furthermore, this study highlights the need for further studies to evaluate galectins in HNSCC and clarify the role of individual Gals in the patient’s stratification.
Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with a poor prognosis. Galectins (Gal) have been the subject of intensive research, but the comparative prognostic value of each Gal type is not yet understood. Therefore, a literature search for evaluating galectins as prognostic biomarkers in HNSCC was conducted. The relationship between Gal expression in HNSCC with HPV and TP53 mutational status was assessed using the UALCAN database. The impact of these biomarkers on prognosis was analyzed using ToPP and CPPA web tools. The expression of galectins in the tumor microenvironment and the impact on prognosis depending on the cancer immune subtype were analyzed using single-cell RNA sequencing. Gal-1 and Gal-3BP were shown to be promising biomarkers with a triple function for the prediction of HPV and TP53 mutational status, stratification of the HNSCC prognosis, and prediction of the response to treatment. In addition, these two galectins have been shown to be most influenced by the tumor microenvironment of HNSCC. Gal-1 and Gal-3BP are the most promising galectins in HNSCC. Furthermore, this study highlights the need for further studies to evaluate galectins in HNSCC and clarify the role of individual Gals in the patient's stratification.Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with a poor prognosis. Galectins (Gal) have been the subject of intensive research, but the comparative prognostic value of each Gal type is not yet understood. Therefore, a literature search for evaluating galectins as prognostic biomarkers in HNSCC was conducted. The relationship between Gal expression in HNSCC with HPV and TP53 mutational status was assessed using the UALCAN database. The impact of these biomarkers on prognosis was analyzed using ToPP and CPPA web tools. The expression of galectins in the tumor microenvironment and the impact on prognosis depending on the cancer immune subtype were analyzed using single-cell RNA sequencing. Gal-1 and Gal-3BP were shown to be promising biomarkers with a triple function for the prediction of HPV and TP53 mutational status, stratification of the HNSCC prognosis, and prediction of the response to treatment. In addition, these two galectins have been shown to be most influenced by the tumor microenvironment of HNSCC. Gal-1 and Gal-3BP are the most promising galectins in HNSCC. Furthermore, this study highlights the need for further studies to evaluate galectins in HNSCC and clarify the role of individual Gals in the patient's stratification.
Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with a poor prognosis. Galectins (Gal) have been the subject of intensive research, but the comparative prognostic value of each Gal type is not yet understood. Therefore, a literature search for evaluating galectins as prognostic biomarkers in HNSCC was conducted. The relationship between Gal expression in HNSCC with HPV and mutational status was assessed using the UALCAN database. The impact of these biomarkers on prognosis was analyzed using ToPP and CPPA web tools. The expression of galectins in the tumor microenvironment and the impact on prognosis depending on the cancer immune subtype were analyzed using single-cell RNA sequencing. and were shown to be promising biomarkers with a triple function for the prediction of HPV and mutational status, stratification of the HNSCC prognosis, and prediction of the response to treatment. In addition, these two galectins have been shown to be most influenced by the tumor microenvironment of HNSCC. and are the most promising galectins in HNSCC. Furthermore, this study highlights the need for further studies to evaluate galectins in HNSCC and clarify the role of individual Gals in the patient's stratification.
Audience Academic
Author Santos, Lucio
Barros, Oriana
D’Agostino, Vito Giuseppe
Ferreira, Rita
Vitorino, Rui
AuthorAffiliation 4 LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal; ritaferreira@ua.pt
1 Department of Medical Sciences, Institute of Biomedicine iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal; orianamirandabarros@gmail.com
5 UnIC, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
2 Experimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Surgical Department of Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto. CCC), 4200-072 Porto, Portugal; llarasantos@gmail.com
3 Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy; vito.dagostino@unitn.it
AuthorAffiliation_xml – name: 3 Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy; vito.dagostino@unitn.it
– name: 4 LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal; ritaferreira@ua.pt
– name: 2 Experimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Surgical Department of Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto. CCC), 4200-072 Porto, Portugal; llarasantos@gmail.com
– name: 5 UnIC, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
– name: 1 Department of Medical Sciences, Institute of Biomedicine iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal; orianamirandabarros@gmail.com
Author_xml – sequence: 1
  givenname: Oriana
  orcidid: 0000-0002-0014-2282
  surname: Barros
  fullname: Barros, Oriana
– sequence: 2
  givenname: Vito Giuseppe
  orcidid: 0000-0003-3379-2254
  surname: D’Agostino
  fullname: D’Agostino, Vito Giuseppe
– sequence: 3
  givenname: Lucio
  surname: Santos
  fullname: Santos, Lucio
– sequence: 4
  givenname: Rita
  orcidid: 0000-0002-6872-4051
  surname: Ferreira
  fullname: Ferreira, Rita
– sequence: 5
  givenname: Rui
  orcidid: 0000-0003-3636-5805
  surname: Vitorino
  fullname: Vitorino, Rui
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38540141$$D View this record in MEDLINE/PubMed
BookMark eNqNUttu1DAQjVARLaV_gJAlXvqyxbdczAuqFnqRCkVAn62JMwleEntrJ4v693jZUrpVJbAfbI3POZ45M8-zHecdZtlLRo-EUPRNbf2AjTXWYWScCppz9STb45yXM0VztXPvvpsdxLigaSkmKiafZbuiyiVlku1l_guubLSjdR35OPWjnV0O1kTyHkYgoydXLsAKe3IKPZqEigQi-Rx853wcrSEnYEYfIrGOnCE0BFxDPqH5Qb5eTzD4KZI59j2ZQ0i5-gFeZE9b6CMe3J772dXJh2_zs9nF5en5_PhiZvKSjrOmZlCUHAFRMlU0rSpqLiRnJSheKwnSGC5aji0vpWilUKVp6oKrGhmrciP2s_ONbuNhoZfBDhButAerfwd86DSEVECPulatKQ1nnLW1xEJUDUUlBG140zIBa618ozW5Jdz8hL6_E2RUr_uhH-tH4r3b8JZTnV4NujFAv5XM9ouz33XnV0lVFRWvaFI4vFUI_nrCOOrBRpMMBYfJWy1SEyktRMkT9PUD6MJPwSWPNVdKVBVVpfiL6lI_tXWtTx-btag-LquKS1HxIqGOHkGl3WAajjSJrU3xLcKr-5XelfhnzhLg7QZggo8xYKuNHWG0fl247f_lo3xA_i_7fwFmO_41
CitedBy_id crossref_primary_10_1007_BF01486048
Cites_doi 10.7314/APJCP.2014.15.5.2145
10.3109/00016489.2013.868603
10.1007/s00432-005-0040-1
10.1158/0008-5472.CAN-10-0761
10.1097/MLG.0b013e31817b0718
10.1016/j.tranon.2019.10.001
10.1158/0008-5472.CAN-15-1793
10.1038/nm.4314
10.1016/j.ejca.2004.06.025
10.1038/s41392-020-00280-x
10.1172/JCI129025
10.47162/RJME.62.1.13
10.1200/JCO.2002.01.078
10.1186/s12885-018-4726-6
10.1371/journal.pone.0038708
10.1016/j.cell.2014.01.043
10.1126/science.1148536
10.1016/j.imbio.2015.04.004
10.1186/s12885-016-2679-1
10.1021/acs.biomac.0c00358
10.1158/2326-6066.CIR-14-0150
10.3389/fimmu.2018.02190
10.1093/glycob/cwl037
10.3342/ceo.2009.2.1.13
10.1016/S0006-291X(03)00151-7
10.1016/j.clim.2008.01.006
10.1039/D0SC00293C
10.18632/oncotarget.17718
10.1016/j.prp.2011.02.004
10.1002/ijc.27550
10.3390/ijms20163933
10.1016/j.humpath.2016.01.014
10.1111/aji.12795
10.1158/0008-5472.CAN-08-1245
10.1074/jbc.M114.603464
10.18632/oncotarget.10981
10.1093/nar/gkq537
10.1200/JCO.2005.02.0206
10.18632/oncotarget.16208
10.3892/ol.2017.5649
10.1016/j.oraloncology.2006.06.010
10.4049/jimmunol.176.2.778
10.1016/j.neo.2017.05.002
10.1369/jhc.2009.952960
10.1007/s12105-020-01195-3
10.1158/0008-5472.CAN-18-2244
10.4049/jimmunol.177.2.796
10.1158/2326-6066.CIR-14-0201
10.1038/s41598-020-73498-y
10.3390/cancers11020261
10.1093/nar/gkac959
10.1007/s12253-013-9603-7
10.4049/jimmunol.165.7.3722
10.1126/scisignal.aaw7095
10.1016/j.cub.2020.06.081
10.1084/jem.20132687
10.1136/jitc-2021-002371
10.1093/nar/gky1129
10.1038/sj.cdd.4401009
10.1136/jclinpath-2016-203754
10.1002/cam4.195
10.1084/jem.20060210
10.1007/s12079-021-00624-4
10.1016/j.cca.2014.12.038
10.1016/j.molimm.2018.06.003
10.1093/nar/gkaa1074
10.1111/j.1365-2559.2008.02973.x
10.6004/jnccn.2020.0031
10.1177/0145561319893861
10.1074/jbc.M117.783431
10.1038/cdd.2010.148
10.1007/s00432-010-0810-2
10.1038/s41598-017-10386-y
10.1016/j.oraloncology.2007.03.004
10.1038/jid.2011.335
10.1245/ASO.2006.08.033
10.1093/glycob/cwl025
10.1016/j.cellsig.2019.109359
10.1016/j.intimp.2017.01.006
10.1155/2019/9827147
10.1080/2162402X.2021.1892265
10.1007/s00262-019-02429-2
10.1074/jbc.M312697200
10.1016/j.imlet.2009.10.003
10.30699/ijp.2021.121140.2318
10.1080/2162402X.2016.1163461
10.3892/mmr.2021.12009
10.1186/s12885-017-3920-2
10.4049/jimmunol.175.5.2974
10.1056/NEJMcibr1914890
10.1093/nar/gkab1028
10.1007/s12032-011-9971-3
10.18632/oncotarget.25845
10.1016/j.annonc.2020.07.011
10.1038/sj.onc.1211029
10.1158/1541-7786.MCR-08-0297
10.1093/bioinformatics/bty411
10.1016/j.isci.2022.104190
ContentType Journal Article
Copyright COPYRIGHT 2024 MDPI AG
2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2024 by the authors. 2024
Copyright_xml – notice: COPYRIGHT 2024 MDPI AG
– notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2024 by the authors. 2024
DBID AAYXX
CITATION
NPM
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.3390/biomedicines12030529
DatabaseName CrossRef
PubMed
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
ProQuest Central Student
SciTech Premium Collection
ProQuest Biological Science Collection
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic
PubMed

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 2227-9059
ExternalDocumentID oai_doaj_org_article_b9fc7c2121fb4e638d0e9330d2df13ac
10.3390/biomedicines12030529
PMC10968280
A788243826
38540141
10_3390_biomedicines12030529
Genre Journal Article
GeographicLocations Portugal
GeographicLocations_xml – name: Portugal
GrantInformation_xml – fundername: Fundação para a Ciência e Tecnologia
  grantid: FCT0
– fundername: Portuguese Foundation for Science and Technology (FCT), European Union, QREN, FEDER, and COMPETE for funding Institute of Biomedicine (iBiMED)
  grantid: UIDB/04501/2020; POCI-01-0145-FEDER-007628
– fundername: Instituto Português de Oncologia do Porto Francisco Gentil, EPE
  grantid: CI-IPOP-134-2020
– fundername: COST Action INTERCEPTOR
– fundername: LAQV-REQUIMTE
  grantid: UIDB/50006/2020
– fundername: Oriana Barros (University of Aveiro)
GroupedDBID 53G
5VS
8FE
8FH
AADQD
AAFWJ
AAYXX
ACPRK
ADBBV
AFKRA
AFPKN
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
CCPQU
CITATION
EMOBN
GROUPED_DOAJ
GX1
HCIFZ
HYE
IAO
IHR
INH
ITC
KQ8
LK8
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PROAC
RPM
NPM
ABUWG
AZQEC
DWQXO
GNUQQ
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
PUEGO
5PM
ADTOC
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c570t-db1a672eaee4196df96b234217a92b94a4cc23f2ef2743f4397cdb629be1185c3
IEDL.DBID BENPR
ISSN 2227-9059
IngestDate Fri Oct 03 12:34:21 EDT 2025
Sun Oct 26 04:16:53 EDT 2025
Tue Sep 30 17:09:35 EDT 2025
Fri Sep 05 09:32:52 EDT 2025
Sun Jul 13 04:53:50 EDT 2025
Mon Oct 20 22:58:44 EDT 2025
Mon Oct 20 17:06:40 EDT 2025
Thu Jan 02 22:37:58 EST 2025
Thu Apr 24 22:59:54 EDT 2025
Thu Oct 16 04:37:01 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords multi-omics
galectins
prognosis
head and neck squamous cell carcinoma
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c570t-db1a672eaee4196df96b234217a92b94a4cc23f2ef2743f4397cdb629be1185c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3379-2254
0000-0002-6872-4051
0000-0002-0014-2282
0000-0003-3636-5805
OpenAccessLink https://www.proquest.com/docview/2993880973?pq-origsite=%requestingapplication%&accountid=15518
PMID 38540141
PQID 2993880973
PQPubID 2032426
ParticipantIDs doaj_primary_oai_doaj_org_article_b9fc7c2121fb4e638d0e9330d2df13ac
unpaywall_primary_10_3390_biomedicines12030529
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10968280
proquest_miscellaneous_3014006372
proquest_journals_2993880973
gale_infotracmisc_A788243826
gale_infotracacademiconefile_A788243826
pubmed_primary_38540141
crossref_citationtrail_10_3390_biomedicines12030529
crossref_primary_10_3390_biomedicines12030529
PublicationCentury 2000
PublicationDate 20240227
PublicationDateYYYYMMDD 2024-02-27
PublicationDate_xml – month: 2
  year: 2024
  text: 20240227
  day: 27
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Biomedicines
PublicationTitleAlternate Biomedicines
PublicationYear 2024
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Walzel (ref_100) 2006; 16
Chang (ref_16) 2014; 134
Severson (ref_66) 2015; 3
Rabinovich (ref_89) 2002; 9
Patru (ref_12) 2021; 62
Ghasemi (ref_17) 2021; 16
Chen (ref_60) 2017; 7
Croci (ref_65) 2014; 156
Sturgill (ref_51) 2021; 10
DeBerardinis (ref_4) 2020; 382
Seki (ref_83) 2008; 127
Pereira (ref_57) 2019; 2019
Pfister (ref_2) 2020; 18
Curti (ref_106) 2021; 9
Ferrazzo (ref_30) 2007; 43
Fik (ref_19) 2013; 42
Peng (ref_88) 2008; 68
Saussez (ref_103) 2008; 118
Li (ref_80) 2017; 44
Li (ref_104) 2021; 23
Noda (ref_25) 2016; 52
Nam (ref_68) 2017; 8
Qi (ref_56) 2019; 68
Chan (ref_28) 2014; 15
Nakajima (ref_55) 2016; 76
Colomb (ref_82) 2017; 292
Paron (ref_94) 2003; 302
Koguchi (ref_92) 2006; 203
Haklai (ref_95) 2004; 279
Chung (ref_97) 2000; 165
Camby (ref_91) 2006; 16
Valach (ref_39) 2012; 131
Suzuki (ref_85) 2012; 40
Sheldon (ref_53) 2017; 8
Gillespie (ref_49) 2022; 50
ref_76
Opperman (ref_87) 2012; 132
Guo (ref_18) 2017; 13
Kouo (ref_63) 2015; 3
Zhong (ref_29) 2010; 136
Aggarwal (ref_6) 2015; 442
Dong (ref_8) 2009; 2
Enninga (ref_77) 2018; 79
Anderson (ref_3) 2020; 30
Teymoortash (ref_34) 2006; 132
Szklarczyk (ref_48) 2021; 49
Wang (ref_86) 2014; 289
Daley (ref_64) 2017; 23
Alves (ref_11) 2011; 207
Sandberg (ref_71) 2018; 9
Blasko (ref_90) 2010; 127
Anderson (ref_102) 2007; 318
Han (ref_46) 2023; 51
Plzak (ref_13) 2001; 19
ref_58
Liu (ref_50) 2018; 34
Wang (ref_32) 2013; 19
Madireddi (ref_70) 2014; 211
Muniz (ref_27) 2015; 220
ref_59
Luo (ref_78) 2018; 101
Xu (ref_7) 2000; 17
Saussez (ref_31) 2007; 30
Tokmak (ref_22) 2021; 100
Zhong (ref_73) 2020; 13
Donaldson (ref_47) 2010; 38
Noda (ref_26) 2017; 70
Toti (ref_54) 2021; 15
Zhang (ref_107) 2019; 63
ref_67
Coppock (ref_37) 2021; 15
Baker (ref_81) 2016; 5
Stillman (ref_96) 2006; 176
Saussez (ref_42) 2006; 13
Vuong (ref_72) 2019; 79
Machiels (ref_1) 2020; 31
Mesquita (ref_10) 2016; 273
Le (ref_9) 2005; 23
Chiang (ref_35) 2008; 44
Saussez (ref_15) 2008; 52
Piantelli (ref_38) 2002; 20
Corapi (ref_74) 2018; 9
Balakrishnan (ref_52) 2020; 21
Detjen (ref_98) 2011; 18
AbuSamra (ref_69) 2019; 12
Demotte (ref_84) 2010; 70
Jin (ref_75) 2020; 5
Cludts (ref_5) 2009; 29
Chandrashekar (ref_43) 2017; 19
Hsieh (ref_101) 2008; 27
Wu (ref_14) 2009; 7
Aimjongjun (ref_33) 2020; 10
Plzak (ref_21) 2004; 40
Miranda (ref_24) 2009; 57
Dai (ref_93) 2005; 175
Acikalin (ref_23) 2012; 29
You (ref_61) 2016; 7
Coker (ref_45) 2019; 47
ref_41
ref_40
Hossaka (ref_36) 2013; 10
Mardani (ref_105) 2018; 19
Matsukawa (ref_20) 2014; 3
Nambiar (ref_62) 2019; 129
Ouyang (ref_44) 2022; 25
Li (ref_79) 2020; 11
Rossi (ref_99) 2006; 177
References_xml – volume: 15
  start-page: 2145
  year: 2014
  ident: ref_28
  article-title: Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers
  publication-title: Asian Pac. J. Cancer Prev. APJCP
  doi: 10.7314/APJCP.2014.15.5.2145
– volume: 134
  start-page: 536
  year: 2014
  ident: ref_16
  article-title: Galectin-1 overexpression in nasopharyngeal carcinoma: Effect on survival
  publication-title: Acta Oto-Laryngol.
  doi: 10.3109/00016489.2013.868603
– volume: 132
  start-page: 51
  year: 2006
  ident: ref_34
  article-title: Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-005-0040-1
– volume: 70
  start-page: 7476
  year: 2010
  ident: ref_84
  article-title: A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-0761
– volume: 118
  start-page: 1583
  year: 2008
  ident: ref_103
  article-title: Galectin-3 upregulation during tumor progression in head and neck cancer
  publication-title: Laryngoscope
  doi: 10.1097/MLG.0b013e31817b0718
– volume: 13
  start-page: 57
  year: 2020
  ident: ref_73
  article-title: Targeting Tumor Microenvironment by Small-Molecule Inhibitors
  publication-title: Transl. Oncol.
  doi: 10.1016/j.tranon.2019.10.001
– volume: 76
  start-page: 1391
  year: 2016
  ident: ref_55
  article-title: Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-1793
– volume: 23
  start-page: 556
  year: 2017
  ident: ref_64
  article-title: Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance
  publication-title: Nat. Med.
  doi: 10.1038/nm.4314
– volume: 40
  start-page: 2324
  year: 2004
  ident: ref_21
  article-title: Galectin-3—An emerging prognostic indicator in advanced head and neck carcinoma
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2004.06.025
– volume: 5
  start-page: 166
  year: 2020
  ident: ref_75
  article-title: The updated landscape of tumor microenvironment and drug repurposing
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00280-x
– volume: 10
  start-page: 428
  year: 2013
  ident: ref_36
  article-title: Detection of galectins during malignant transformation of oral cells
  publication-title: Dent. Res. J.
– volume: 129
  start-page: 5553
  year: 2019
  ident: ref_62
  article-title: Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI129025
– volume: 62
  start-page: 133
  year: 2021
  ident: ref_12
  article-title: Immunohistochemical evaluation of D2-40, Galectin-3, Maspin and MCM7 expression in palate squamous cell carcinomas
  publication-title: Rom. J. Morphol. Embryol. Rev. Roum. Morphol. Embryol.
  doi: 10.47162/RJME.62.1.13
– volume: 20
  start-page: 3850
  year: 2002
  ident: ref_38
  article-title: Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma
  publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.
  doi: 10.1200/JCO.2002.01.078
– ident: ref_40
  doi: 10.1186/s12885-018-4726-6
– ident: ref_67
  doi: 10.1371/journal.pone.0038708
– volume: 156
  start-page: 744
  year: 2014
  ident: ref_65
  article-title: Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
  publication-title: Cell
  doi: 10.1016/j.cell.2014.01.043
– volume: 318
  start-page: 1141
  year: 2007
  ident: ref_102
  article-title: Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells
  publication-title: Science
  doi: 10.1126/science.1148536
– volume: 220
  start-page: 1006
  year: 2015
  ident: ref_27
  article-title: Galectin-9 as an important marker in the differential diagnosis between oral squamous cell carcinoma, oral leukoplakia and oral lichen planus
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2015.04.004
– ident: ref_76
  doi: 10.1186/s12885-016-2679-1
– volume: 21
  start-page: 2645
  year: 2020
  ident: ref_52
  article-title: Multifunctional Core-Shell Glyconanoparticles for Galectin-3-Targeted, Trigger-Responsive Combination Chemotherapy
  publication-title: Biomacromolecules
  doi: 10.1021/acs.biomac.0c00358
– volume: 3
  start-page: 412
  year: 2015
  ident: ref_63
  article-title: Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0150
– volume: 42
  start-page: 166
  year: 2013
  ident: ref_19
  article-title: Loss of adhesion/growth-regulatory galectin-9 from squamous cell epithelium in head and neck carcinomas
  publication-title: J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol.
– volume: 9
  start-page: 2190
  year: 2018
  ident: ref_74
  article-title: Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.02190
– volume: 19
  start-page: 689
  year: 2018
  ident: ref_105
  article-title: Galectin-3 Serum Levels Could Help Clinicians Screen for Salivary Gland Tumor Patients
  publication-title: Asian Pac. J. Cancer Prev. APJCP
– volume: 16
  start-page: 1262
  year: 2006
  ident: ref_100
  article-title: Effects of N-glycan processing inhibitors on signaling events and induction of apoptosis in galectin-1-stimulated Jurkat T lymphocytes
  publication-title: Glycobiology
  doi: 10.1093/glycob/cwl037
– volume: 2
  start-page: 13
  year: 2009
  ident: ref_8
  article-title: Galectin-8 expression in laryngeal squamous cell carcinoma
  publication-title: Clin. Exp. Otorhinolaryngol.
  doi: 10.3342/ceo.2009.2.1.13
– volume: 302
  start-page: 545
  year: 2003
  ident: ref_94
  article-title: Nuclear localization of Galectin-3 in transformed thyroid cells: A role in transcriptional regulation
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/S0006-291X(03)00151-7
– volume: 127
  start-page: 78
  year: 2008
  ident: ref_83
  article-title: Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis
  publication-title: Clin. Immunol.
  doi: 10.1016/j.clim.2008.01.006
– volume: 11
  start-page: 7429
  year: 2020
  ident: ref_79
  article-title: A tumor acidity activatable and Ca(2+)-assisted immuno-nanoagent enhances breast cancer therapy and suppresses cancer recurrence
  publication-title: Chem. Sci.
  doi: 10.1039/D0SC00293C
– volume: 8
  start-page: 49484
  year: 2017
  ident: ref_53
  article-title: Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17718
– volume: 207
  start-page: 236
  year: 2011
  ident: ref_11
  article-title: Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue
  publication-title: Pathol. Res. Pract.
  doi: 10.1016/j.prp.2011.02.004
– volume: 131
  start-page: 2499
  year: 2012
  ident: ref_39
  article-title: Smooth muscle actin-expressing stromal fibroblasts in head and neck squamous cell carcinoma: Increased expression of galectin-1 and induction of poor prognosis factors
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.27550
– ident: ref_59
  doi: 10.3390/ijms20163933
– volume: 52
  start-page: 101
  year: 2016
  ident: ref_25
  article-title: Galectin-1 is a useful marker for detecting neoplastic squamous cells in oral cytology smears
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2016.01.014
– volume: 79
  start-page: e12795
  year: 2018
  ident: ref_77
  article-title: Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy
  publication-title: Am. J. Reprod. Immunol.
  doi: 10.1111/aji.12795
– volume: 68
  start-page: 7228
  year: 2008
  ident: ref_88
  article-title: Tumor-associated galectin-3 modulates the function of tumor-reactive T cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-1245
– volume: 289
  start-page: 33311
  year: 2014
  ident: ref_86
  article-title: Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M114.603464
– volume: 7
  start-page: 57099
  year: 2016
  ident: ref_61
  article-title: MiRNA-22 inhibits oncogene galectin-1 in hepatocellular carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10981
– volume: 38
  start-page: W214
  year: 2010
  ident: ref_47
  article-title: The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkq537
– volume: 23
  start-page: 8932
  year: 2005
  ident: ref_9
  article-title: Galectin-1: A link between tumor hypoxia and tumor immune privilege
  publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.
  doi: 10.1200/JCO.2005.02.0206
– volume: 8
  start-page: 35804
  year: 2017
  ident: ref_68
  article-title: Binding of galectin-1 to integrin beta1 potentiates drug resistance by promoting survivin expression in breast cancer cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16208
– volume: 13
  start-page: 1919
  year: 2017
  ident: ref_18
  article-title: Galectin-7 promotes the invasiveness of human oral squamous cell carcinoma cells via activation of ERK and JNK signaling
  publication-title: Oncol. Lett.
  doi: 10.3892/ol.2017.5649
– volume: 29
  start-page: 4933
  year: 2009
  ident: ref_5
  article-title: Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7
  publication-title: Anticancer. Res.
– volume: 43
  start-page: 580
  year: 2007
  ident: ref_30
  article-title: Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2006.06.010
– volume: 176
  start-page: 778
  year: 2006
  ident: ref_96
  article-title: Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.176.2.778
– volume: 19
  start-page: 649
  year: 2017
  ident: ref_43
  article-title: UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2017.05.002
– volume: 57
  start-page: 665
  year: 2009
  ident: ref_24
  article-title: Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis
  publication-title: J. Histochem. Cytochem. Off. J. Histochem. Soc.
  doi: 10.1369/jhc.2009.952960
– volume: 15
  start-page: 163
  year: 2021
  ident: ref_37
  article-title: Galectin-3 Expression in High-Risk HPV-Positive and Negative Head & Neck Squamous Cell Carcinomas and Regional Lymph Node Metastases
  publication-title: Head Neck Pathol.
  doi: 10.1007/s12105-020-01195-3
– volume: 79
  start-page: 1480
  year: 2019
  ident: ref_72
  article-title: An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-2244
– volume: 177
  start-page: 796
  year: 2006
  ident: ref_99
  article-title: Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.177.2.796
– volume: 3
  start-page: 620
  year: 2015
  ident: ref_66
  article-title: PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0201
– volume: 273
  start-page: 237
  year: 2016
  ident: ref_10
  article-title: Association of immunoexpression of the galectins-3 and -7 with histopathological and clinical parameters in oral squamous cell carcinoma in young patients
  publication-title: Eur. Arch. Oto-Rhino-Laryngol. Off. J. Eur. Fed. Oto-Rhino-Laryngol. Soc. EUFOS Affil. Ger. Soc. Oto-Rhino-Laryngol.–Head Neck Surg.
– volume: 10
  start-page: 16462
  year: 2020
  ident: ref_33
  article-title: Lectin affinity chromatography and quantitative proteomic analysis reveal that galectin-3 is associated with metastasis in nasopharyngeal carcinoma
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-73498-y
– ident: ref_58
  doi: 10.3390/cancers11020261
– volume: 51
  start-page: D1425
  year: 2023
  ident: ref_46
  article-title: TISCH2: Expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkac959
– volume: 19
  start-page: 461
  year: 2013
  ident: ref_32
  article-title: Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/beta-catenin-dependent pathway
  publication-title: Pathol. Oncol. Res. POR
  doi: 10.1007/s12253-013-9603-7
– volume: 165
  start-page: 3722
  year: 2000
  ident: ref_97
  article-title: Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.165.7.3722
– volume: 12
  start-page: eaaw7095
  year: 2019
  ident: ref_69
  article-title: Galectin-3 initiates epithelial-stromal paracrine signaling to shape the proteolytic microenvironment during corneal repair
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.aaw7095
– volume: 30
  start-page: R921
  year: 2020
  ident: ref_3
  article-title: The tumor microenvironment
  publication-title: Curr. Biol. CB
  doi: 10.1016/j.cub.2020.06.081
– volume: 211
  start-page: 1433
  year: 2014
  ident: ref_70
  article-title: Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20132687
– volume: 9
  start-page: e002371
  year: 2021
  ident: ref_106
  article-title: Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2021-002371
– volume: 40
  start-page: 1831
  year: 2012
  ident: ref_85
  article-title: MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis
  publication-title: Int. J. Oncol.
– volume: 47
  start-page: D917
  year: 2019
  ident: ref_45
  article-title: canSAR: Update to the cancer translational research and drug discovery knowledgebase
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gky1129
– volume: 17
  start-page: 271
  year: 2000
  ident: ref_7
  article-title: Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms
  publication-title: Int. J. Oncol.
– volume: 9
  start-page: 661
  year: 2002
  ident: ref_89
  article-title: Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms
  publication-title: Cell Death Differ.
  doi: 10.1038/sj.cdd.4401009
– volume: 70
  start-page: 126
  year: 2017
  ident: ref_26
  article-title: Galectin-1 expression is associated with tumour immunity and prognosis in gingival squamous cell carcinoma
  publication-title: J. Clin. Pathol.
  doi: 10.1136/jclinpath-2016-203754
– volume: 3
  start-page: 349
  year: 2014
  ident: ref_20
  article-title: Galectin-7 as a potential predictive marker of chemo- and/or radio-therapy resistance in oral squamous cell carcinoma
  publication-title: Cancer Med.
  doi: 10.1002/cam4.195
– volume: 203
  start-page: 1413
  year: 2006
  ident: ref_92
  article-title: Dysregulated T cell expression of TIM3 in multiple sclerosis
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20060210
– volume: 15
  start-page: 405
  year: 2021
  ident: ref_54
  article-title: Activated fibroblasts enhance cancer cell migration by microvesicles-mediated transfer of Galectin-1
  publication-title: J. Cell Commun. Signal.
  doi: 10.1007/s12079-021-00624-4
– volume: 442
  start-page: 13
  year: 2015
  ident: ref_6
  article-title: Galectin-1 and galectin-3: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population
  publication-title: Clin. Chim. Acta Int. J. Clin. Chem.
  doi: 10.1016/j.cca.2014.12.038
– volume: 101
  start-page: 80
  year: 2018
  ident: ref_78
  article-title: Galectin-7 promotes proliferation and Th1/2 cells polarization toward Th1 in activated CD4+ T cells by inhibiting The TGFbeta/Smad3 pathway
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2018.06.003
– volume: 49
  start-page: D605
  year: 2021
  ident: ref_48
  article-title: The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkaa1074
– volume: 52
  start-page: 483
  year: 2008
  ident: ref_15
  article-title: Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2008.02973.x
– volume: 18
  start-page: 873
  year: 2020
  ident: ref_2
  article-title: Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
  publication-title: J. Natl. Compr. Cancer Netw. JNCCN
  doi: 10.6004/jnccn.2020.0031
– volume: 100
  start-page: 578S
  year: 2021
  ident: ref_22
  article-title: Evaluation and Prognostic Significance of Galectin-3 Expression in Oral Squamous Cell Carcinoma
  publication-title: Ear Nose Throat J.
  doi: 10.1177/0145561319893861
– volume: 292
  start-page: 8381
  year: 2017
  ident: ref_82
  article-title: Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M117.783431
– volume: 18
  start-page: 806
  year: 2011
  ident: ref_98
  article-title: Galectin-1 sensitizes carcinoma cells to anoikis via the fibronectin receptor alpha5beta1-integrin
  publication-title: Cell Death Differ.
  doi: 10.1038/cdd.2010.148
– volume: 136
  start-page: 1527
  year: 2010
  ident: ref_29
  article-title: Overexpression of Galectin-1 is negatively correlated with pathologic differentiation grade in oral squamous cell carcinoma
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-010-0810-2
– volume: 7
  start-page: 10349
  year: 2017
  ident: ref_60
  article-title: The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-10386-y
– volume: 44
  start-page: 325
  year: 2008
  ident: ref_35
  article-title: Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2007.03.004
– volume: 132
  start-page: 410
  year: 2012
  ident: ref_87
  article-title: Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity
  publication-title: J. Investig. Dermatol.
  doi: 10.1038/jid.2011.335
– volume: 13
  start-page: 999
  year: 2006
  ident: ref_42
  article-title: Galectin 7 (p53-induced gene 1): A new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/ASO.2006.08.033
– volume: 16
  start-page: 137R
  year: 2006
  ident: ref_91
  article-title: Galectin-1: A small protein with major functions
  publication-title: Glycobiology
  doi: 10.1093/glycob/cwl025
– volume: 63
  start-page: 109359
  year: 2019
  ident: ref_107
  article-title: Increased LGALS3BP promotes proliferation and migration of oral squamous cell carcinoma via PI3K/AKT pathway
  publication-title: Cell. Signal.
  doi: 10.1016/j.cellsig.2019.109359
– volume: 44
  start-page: 153
  year: 2017
  ident: ref_80
  article-title: Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2017.01.006
– volume: 2019
  start-page: 9827147
  year: 2019
  ident: ref_57
  article-title: Galectin-3 Regulates the Expression of Tumor Glycosaminoglycans and Increases the Metastatic Potential of Breast Cancer
  publication-title: J. Oncol.
  doi: 10.1155/2019/9827147
– volume: 10
  start-page: 1892265
  year: 2021
  ident: ref_51
  article-title: Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2021.1892265
– volume: 68
  start-page: 2067
  year: 2019
  ident: ref_56
  article-title: Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response
  publication-title: Cancer Immunol. Immunother. CII
  doi: 10.1007/s00262-019-02429-2
– volume: 279
  start-page: 34922
  year: 2004
  ident: ref_95
  article-title: Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M312697200
– volume: 127
  start-page: 108
  year: 2010
  ident: ref_90
  article-title: Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1
  publication-title: Immunol. Lett.
  doi: 10.1016/j.imlet.2009.10.003
– volume: 16
  start-page: 195
  year: 2021
  ident: ref_17
  article-title: Reduced Expression of Galectin-8 May Contribute in Carcinogenic Pathway of Head and Neck Squamous Cell Carcinoma
  publication-title: Iran. J. Pathol.
  doi: 10.30699/ijp.2021.121140.2318
– volume: 5
  start-page: e1163461
  year: 2016
  ident: ref_81
  article-title: Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1163461
– volume: 23
  start-page: 370
  year: 2021
  ident: ref_104
  article-title: Galectin-3 facilitates the proliferation and migration of nasopharyngeal carcinoma cells via activation of the ERK1/2 and Akt signaling pathways, and is positively correlated with the inflammatory state of nasopharyngeal carcinoma
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2021.12009
– ident: ref_41
  doi: 10.1186/s12885-017-3920-2
– volume: 19
  start-page: 59
  year: 2001
  ident: ref_13
  article-title: Expression of galectin-3-reactive ligands in squamous cancer and normal epithelial cells as a marker of differentiation
  publication-title: Int. J. Oncol.
– volume: 30
  start-page: 1109
  year: 2007
  ident: ref_31
  article-title: High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas
  publication-title: Int. J. Oncol.
– volume: 175
  start-page: 2974
  year: 2005
  ident: ref_93
  article-title: Galectin-9 induces maturation of human monocyte-derived dendritic cells
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.175.5.2974
– volume: 382
  start-page: 869
  year: 2020
  ident: ref_4
  article-title: Tumor Microenvironment, Metabolism, and Immunotherapy
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMcibr1914890
– volume: 50
  start-page: D687
  year: 2022
  ident: ref_49
  article-title: The reactome pathway knowledgebase 2022
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkab1028
– volume: 29
  start-page: 742
  year: 2012
  ident: ref_23
  article-title: Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-011-9971-3
– volume: 9
  start-page: 31502
  year: 2018
  ident: ref_71
  article-title: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio–Increased expression of galectin-1 in tumors with high stromal content
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25845
– volume: 31
  start-page: 1462
  year: 2020
  ident: ref_1
  article-title: Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1016/j.annonc.2020.07.011
– volume: 27
  start-page: 3746
  year: 2008
  ident: ref_101
  article-title: Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1211029
– volume: 7
  start-page: 311
  year: 2009
  ident: ref_14
  article-title: Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons
  publication-title: Mol. Cancer Res. MCR
  doi: 10.1158/1541-7786.MCR-08-0297
– volume: 34
  start-page: 3771
  year: 2018
  ident: ref_50
  article-title: GSCALite: A web server for gene set cancer analysis
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/bty411
– volume: 25
  start-page: 104190
  year: 2022
  ident: ref_44
  article-title: ToPP: Tumor online prognostic analysis platform for prognostic feature selection and clinical patient subgroup selection
  publication-title: iScience
  doi: 10.1016/j.isci.2022.104190
SSID ssj0000913814
Score 2.2577527
Snippet Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with a poor prognosis. Galectins (Gal) have been the subject of intensive research, but the...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 529
SubjectTerms B cells
Biomarkers
Cancer therapies
Cells
Chemotherapy
Comparative analysis
Datasets
Development and progression
galectins
Gene expression
Genomics
Head & neck cancer
Head and neck carcinoma
head and neck squamous cell carcinoma
Human papillomavirus
Internet software
Medical prognosis
Metastasis
multi-omics
Papillomavirus infections
Prognosis
RNA
RNA sequencing
Squamous cell carcinoma
Survival analysis
Tumor microenvironment
Tumor proteins
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQL8AB8SZQkJGQOIVubOd1LAvLikNBwEq9WX5FrJo6pcmq6r9nxklDAkjlwDV2otj-ZjxfMv6GkFeC5RZYQhovMp3FwqBJFQIWhANzMwr1TkK2xVG23oiPx-nxpNQX5oT18sD9xB3osjK5AQebVFo4QItdOCThltkq4cqg910U5YRMBR9cJrAVif6sHAdef9CfZg9_q9uEIcxDVPlrLwqS_X865snO9HvW5M2dP1OXF6quJ1vS6i65M8SS9LAfwz1yw_n75PZEYfABab6E0-OY20zDWdv40-nWtPSd6hTtGrrxWH6oph8Ufr7f-paqln4-bzD9Dp5KV305Hrr1dA1ooMpbeuTMCf36Y6fwqwFdurqmS6xI5JtT9ZBsVu-_LdfxUGMhNmm-6GKrE5XlzCnnBBijrcpMMy6AqKiS6VIoYQzjFXMV0FdeYfhirM5YqR1Qk9TwR2TPN949ITRLnXHcooJZJTJllEuzCh5eaAgDbC4iwq9mW5pBgBzrYNQSiAiukfzbGkUkHu866wU4run_Fhdy7Ivy2eECgEoOoJLXgSoirxEGEo0cXtGo4awCDBTlsuRhDsQEf6FmEdmf9QTjNPPmKyDJwTm0EiIAlOApcx6Rl2Mz3okJb97B4snAfCF8zFlEHve4G4fECwizE5FEpJghcjbmeYvffg_S4QkwVuDYi4i8GcH7T9P69H9M6zNyi0FMGBQB8n2y153v3HOI6Tr9IpjvT--nTFA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB5B9wAceD8CCzISEqdsG9txmhMqhVJxKCug0nKyHMeBarNJaVIQ_HpmkrS0CxKPax1HdTwef5898w3AE8mjFFlC6A9UonxpaUkNJU6IQOZmDemdNNEWMzWdy9cn4Ul34FZ1YZVIxReNk6Y8TT9GANAPeF_0Qx73l2n27Et3khREFFRIHOUiHKgQsXgPDuaz49EHqii36dvmywnk9v02o725sa4CTqbeIMuf-1Ej2_-rc97Znc5HTl5aF0vz7avJ851taXIN9GZAbTTK6dG6To7s93Naj_8_4utwtUOsbNSa2A244IqbcGVHx_AWlG-bHHWKoGZNRq__5mxhK_bC1IbVJZsXVOQoZ68MXRIsioqZih2vSgryw7eySVv0hy0KNkWbY6ZI2czZU_bu89rQ2QQbuzxnY6p7VJRn5jbMJy_fj6d-V8nBt2E0qP00CYyKuDPOSVzyaRarhAuJdMjEPImlkdZykXGXIUkWGYEkmyaKx4lDAhRacQd6RVm4e8BU6KwTKemkZVIZa1yoMnz5MEGwkUbSA7GZT207mXOqtpFrpDtkBfp3VuCBv-21bGU-_vD8czKV7bMk0t38UK4-6m7N6yTObGQRGwRZIh06unTg6Pwo5WkWCGM9eEqGpsmV4F-0psuIwIGSKJceRUh_6KJWeXC49yS6ALvfvDFV3bmgSiPOIKGfOBIePN42U08KqyscTp5u-DWC1Ih7cLe17O2QxBDBfCADD4Z7Nr835v2WYvGpESgPkBcjkx94cLRdHn_1We__a4cHcJkjymw0BqJD6NWrtXuIKLFOHnWu4AdwdWRP
  priority: 102
  providerName: Unpaywall
Title Revisiting Multi-Omics Data to Unravel Galectins as Prognostic Factors in Head and Neck Squamous Cell Carcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/38540141
https://www.proquest.com/docview/2993880973
https://www.proquest.com/docview/3014006372
https://pubmed.ncbi.nlm.nih.gov/PMC10968280
https://www.mdpi.com/2227-9059/12/3/529/pdf?version=1709022184
https://doaj.org/article/b9fc7c2121fb4e638d0e9330d2df13ac
UnpaywallVersion publishedVersion
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2227-9059
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913814
  issn: 2227-9059
  databaseCode: KQ8
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2227-9059
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913814
  issn: 2227-9059
  databaseCode: DOA
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2227-9059
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913814
  issn: 2227-9059
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2227-9059
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913814
  issn: 2227-9059
  databaseCode: M~E
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2227-9059
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913814
  issn: 2227-9059
  databaseCode: RPM
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2227-9059
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000913814
  issn: 2227-9059
  databaseCode: BENPR
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-N7gF4mPgcgTEZCYmnsMZxkuYBoa6sVDyUalBpPEWO7UBF5nT90MR_z52TZi0g4LGJE9Xx3fl-57vfAbwUPNGIEiK_G-exLxSpVE_ggoSI3JQkvhOXbTGOR1Px4SK62IPxphaG0io3NtEZal0pipGfoNkk3pI0Cd_Or3zqGkWnq5sWGrJpraDfOIqxW7DPiRmrA_unZ-PJeRt1IRbMXiDqGroQ8f5JXeXuTrGXASfxd97mzR7lqPx_N9hbO9av2ZS313Yuf1zLstzaqob34KDxMVm_For7sGfsA7i7xTz4EKpzV1VOOc_M1eD6Hy9nasneyZVkq4pNLbUlKtl7SWH9mV0yuWSTRUVpefhWNqzb9LCZZSOUEiatZmOjvrNPV2tJ0QQ2MGXJBtSpyFaX8hFMh2efByO_6b3gqyjprnydBzJOuJHGCFRSXaRxzkOBAEamPE-FFErxsOCmQFgbFuTWKJ3HPM0NQpZIhY-hYytrngCLI6NMqInZrBCxVNJEcYEv7-XoHuhEeBBuvnamGmJy6o9RZghQaI2yP62RB3771Lwm5vjH-FNayHYs0Wq7C9Xia9ZoaZanhUoUiU6RC4OmSXcNRXw010UQSuXBKxKDjJQf_6KSTQ0DTpRotLJ-goCFjlZjD452RqLSqt3bG0HKGqOxzG5E3IMX7W16khLhrMHFyxwiRrcy4R4c1nLXTinsofsdiMCD3o5E7sx5946dfXOU4gEiWcTeXQ9et8L7X5_16d8n8gzucPQCHQdAcgSd1WJtnqMXt8qPG9U8dlEQ_DUdT_pffgKSN0xW
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfG9jB4QHwTGGAkEE9hje0kzcOEtm6lY6NMY5X2FhzbgYos6ZpW0_45_jbunI-1gICXvcaOFefO5_vZd78j5JVgoQaU4LudIAlcoXBJdQUIhANyUxL5Tmy0xTAYjMSHU_90hfxocmEwrLKxidZQ60LhGfkmmE3kLYlC_m5y7mLVKLxdbUpoyLq0gt6yFGN1YseBubwACFdu7e-CvF8z1t876Q3cusqAq_ywM3N14skgZEYaI0AddRoFCeMCXHUZsSQSUijFeMpMCgCOp7iBK50ELEoMOOe-4jDuDbImuIgA_K3t7A2PjttTHmTd7HqiytnjPOpsVln19ta89BguN-vdXu2JtnTA7xvEwg75a_Tm-jyfyMsLmWULW2P_Drld-7R0u1LCu2TF5PfIrQWmw_ukOLZZ7BhjTW3Or_vpbKxKuitnks4KOsqxDFJG30u8RhjnJZUlPZoWGAYIo9J-VRaIjnM6AK2kMtd0aNR3-vl8LvH0gvZMltEeVkbKizP5gIyuRQoPyWpe5OYxoYFvlOEamdRSEUgljR-kMHg3AXdEh8IhvPnbsaqJ0LEeRxYDIEIZxX-SkUPc9q1JRQTyj_47KMi2L9J42wfF9GtcW4U4iVIVKvAevDQRBkyh7hg8YdJMpx6XyiFvUA1iNDbwiUrWORMwUaTtirdDAEh4lRs4ZGOpJxgJtdzcKFJcG6kyvlpSDnnZNuObGHiXGxBebBE4uLEhc8ijSu_aKfEuuPue8BzSXdLIpTkvt-Tjb5bC3APkDFi_45C3rfL-12998veJvCDrg5OPh_Hh_vDgKbnJwAO1_APhBlmdTefmGXiQs-R5vUwp-XLdluEnu1qG0w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJvHxgPgmMMBIIJ6yNraTNA8T2tqVjqFSDSrtLTi2AxVZ0jWtpv2L_FXcOWnWAgJe9ho7Vpw7_3xn3_2OkFeChRq8BN9tB0ngCoVLqiNAIBw8NyWR78RGWwyDwVi8P_FPNsiPZS4MhlUuMdECtS4UnpG3ADaRtyQKeSutwyJGvf7b6ZmLFaTwpnVZTkPWZRb0rqUbq5M8jszFObhz5e5hD2T_mrH-wefuwK0rDrjKD9tzVyeeDEJmpDECVFOnUZAwLsBslxFLIiGFUoynzKTgzPEUN3Olk4BFiQFD3Vccxr1GtvDyC0Bia_9gODpuTnyQgbPjiSp_j_Oo3aoy7O0NeukxXHrW0r3cH20Zgd83i5Xd8tdIzhuLfCovzmWWrWyT_Tvkdm3f0r1KIe-SDZPfI7dWWA_vk-LYZrRjvDW1-b_ux9OJKmlPziWdF3ScY0mkjL6TeKUwyUsqSzqaFRgSCKPSflUiiE5yOgANpTLXdGjUd_rpbCHxJIN2TZbRLlZJyotT-YCMr0QKD8lmXuTmMaGBb5ThGlnVUhFIJY0fpDB4JwHTRIfCIXz5t2NVk6JjbY4sBucIZRT_SUYOcZu3phUpyD_676Mgm75I6W0fFLOvcY0QcRKlKlRgSXhpIgzAom4bPG3STKcel8ohb1ANYgQe-EQl6_wJmChSeMV7IThLeK0bOGR7rScAhlpvXipSXANWGV8uL4e8bJrxTQzCyw0IL7beOJi0IXPIo0rvminxDpj-nvAc0lnTyLU5r7fkk2-WztwDLxr8_rZDdhrl_a_f-uTvE3lBrgNCxB8Oh0dPyU0GxqilIgi3yeZ8tjDPwJicJ8_rVUrJl6sGhp_GVYsC
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB5B9wAceD8CCzISEqdsG9txmhMqhVJxKCug0nKyHMeBarNJaVIQ_HpmkrS0CxKPax1HdTwef5898w3AE8mjFFlC6A9UonxpaUkNJU6IQOZmDemdNNEWMzWdy9cn4Ul34FZ1YZVIxReNk6Y8TT9GANAPeF_0Qx73l2n27Et3khREFFRIHOUiHKgQsXgPDuaz49EHqii36dvmywnk9v02o725sa4CTqbeIMuf-1Ej2_-rc97Znc5HTl5aF0vz7avJ851taXIN9GZAbTTK6dG6To7s93Naj_8_4utwtUOsbNSa2A244IqbcGVHx_AWlG-bHHWKoGZNRq__5mxhK_bC1IbVJZsXVOQoZ68MXRIsioqZih2vSgryw7eySVv0hy0KNkWbY6ZI2czZU_bu89rQ2QQbuzxnY6p7VJRn5jbMJy_fj6d-V8nBt2E0qP00CYyKuDPOSVzyaRarhAuJdMjEPImlkdZykXGXIUkWGYEkmyaKx4lDAhRacQd6RVm4e8BU6KwTKemkZVIZa1yoMnz5MEGwkUbSA7GZT207mXOqtpFrpDtkBfp3VuCBv-21bGU-_vD8czKV7bMk0t38UK4-6m7N6yTObGQRGwRZIh06unTg6Pwo5WkWCGM9eEqGpsmV4F-0psuIwIGSKJceRUh_6KJWeXC49yS6ALvfvDFV3bmgSiPOIKGfOBIePN42U08KqyscTp5u-DWC1Ih7cLe17O2QxBDBfCADD4Z7Nr835v2WYvGpESgPkBcjkx94cLRdHn_1We__a4cHcJkjymw0BqJD6NWrtXuIKLFOHnWu4AdwdWRP
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Revisiting+Multi-Omics+Data+to+Unravel+Galectins+as+Prognostic+Factors+in+Head+and+Neck+Squamous+Cell+Carcinoma&rft.jtitle=Biomedicines&rft.au=Barros%2C+Oriana&rft.au=D%E2%80%99Agostino%2C+Vito+Giuseppe&rft.au=Santos%2C+Lucio&rft.au=Ferreira%2C+Rita&rft.date=2024-02-27&rft.pub=MDPI&rft.eissn=2227-9059&rft.volume=12&rft.issue=3&rft_id=info:doi/10.3390%2Fbiomedicines12030529&rft.externalDocID=PMC10968280
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2227-9059&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2227-9059&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2227-9059&client=summon